Loading...
•
Mar 31, 2022
Orthofix Q1 2022 Earnings Report
Reported a net sales increase of 1% and adjusted EPS of $(0.10).
Key Takeaways
Orthofix Medical Inc. reported first quarter 2022 financial results with net sales of $106.4 million, EPS of $(0.22), and adjusted EPS of $(0.10). The company reaffirmed its 2022 guidance.
Net sales of $106.4 million, an increase of 1% on a reported basis and 2% on a constant currency basis over prior year
New product sales drive solid growth in Biologics, Spinal Implants, and Orthopedics
FDA grants PMA for AccelStim™ bone growth stimulator — LIPUS technology expands our indications into fresh fracture care
FDA clearance received for the TrueLok™ EVO Ring Fixation system, which enables clear radiographic visualization
Orthofix
Orthofix
Orthofix Revenue by Segment
Revenue by Segment
Bone Growth Therapies Revenue
CapyFin.comSpinal Implants, Biologics and Enabling Technologies Revenue
CapyFin.comGlobal Spine Revenue
CapyFin.comGlobal Orthopedics Revenue
CapyFin.com Forward Guidance
The Company expects net sales between $475.0 million and $490.0 million, Adjusted EBITDA between $56.0 million and $61.0 million and Adjusted EPS between $0.58 and $0.73 for the year ended December 31, 2022.
Positive Outlook
- Net sales year-over-year increase of 2% to 5% on a reported basis
- Net sales year-over-year increase of 4% to 7% on a constant currency basis
Challenges Ahead
- Adjusted EBITDA year-over-year decrease of 9% to 0%
- Adjusted EPS year-over-year decrease of 33% to 15%
Revenue & Expenses
Visualization of income flow from segment revenue to net income